Using FR054 to inhibit glycosylation reactions further enhances the anticancer activity of BI-2852 against PDAC cells [181], supporting that the hexosamine biosynthesis pathway is a potential target for the treatment of KRAS-mutant cancers [182]. The gene discussed is KRAS; the disease is cancer.